A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects

Despite currently available antivirals, influenza causes significant morbidity and
mortality, with 226,000 excess hospitalizations and 30,000-50,000 deaths each year in the
United States alone, and more therapies are needed in the armamentarium of anti-influenza
medications including humoral immunity-based agents.

This study will evaluate the pharmacokinetics of an anti-influenza hyperimmune intravenous
immunoglobulin. Beginning with a low dose, subjects will receive anti-influenza intravenous
immunoglobulin (FLU-IVIG) and evaluated on Study Days 0, 3, 7, 14, and 28. The safety and
tolerability is evaluated using symptoms, clinical laboratory tests, and pharmacokinetics.
Utilizing serum antibody responses as determined by hemagglutination inhibition (HAI)
assays, the dose will be escalated as immunogenicity is established.

- INCLUSION CRITERIA:

1. Age greater than or equal to 18 years and less than or equal to 50 years

2. Weight less than or equal to 100 kg

3. Patients must be willing to forgo the seasonal influenza vaccine for 28 days,
and the MMR and varicella vaccines for 3 months post infusion of the study drug

4. Females who are able to become pregnant (i.e., are not postmenopausal, have not
undergone surgical sterilization, and are sexually active with men) must agree
to use at least 1 effective form of contraception from the date of the subject
s signing of the informed consent form through 28 days after the dose of the
study drug

EXCLUSION CRIATERIA:

1. Any chronic medical problem that requires daily oral medications (except Tylenol,
oral contraceptives, vitamins, and seasonal allergy medications), or other medical
history that in the opinion of the investigator significantly increases the risk
associated with IVIG

2. Women who are breast-feeding

3. Positive urine or serum pregnancy test

4. Known sensitivity to IVIG

5. IgA < 7 mg/dL

6. Influenza HAI H1N1 > 1:20

7. Receipt of any vaccination within 30 days prior to study drug administration

8. Pre-existing condition that is associated with an increased risk of thrombosis such
as cryoglobulinemia, hyper-triglyceridemia, or monoclonal gammopathies

9. Estimated glomerular filtration rate (GFR) < 60 mL/min at screening, calculated
using the MDRD formula

10. Medical conditions for which receipt of up to 750 mL volume may be dangerous to the
patient (e.g., decompensated congestive heart failure)

11. Abnormal chemistry panel

-Defined as any clinically significant baseline Grade 1 or greater toxicity, or any
Grade 3 or greater toxicity (regardless of clinical significance) by the toxicity
table

--Evaluating only total CO2 (bicarbonate), creatinine, alkaline phosphatase, ALT,
AST, total bilirubin, and estimated GFR by the MDRD equation

12. Abnormal complete blood count (CBC)

-Defined as any clinically significant baseline Grade 1 or greater toxicity, or any
Grade 3 or greater toxicity (regardless of clinical significance) by the toxicity
table

--Evaluating only the WBC, hemoglobin, hematocrit, and platelets

13. Positive serology for Hepatitis B surface antigen

14. Positive serology for Hepatitis C

15. Positive serology for HIV-1

16. Prior treatment with any investigational drug therapy within 5 half-lives or 30 days,
whichever is longer, prior to study drug administration (i.e., Day 0)

17. Receipt of blood products from 30 days prior to study drug administration (i.e., Day
0) through 28 days after the dose of the study drug

18. Presence of any pre-existing illness that, in the opinion of the investigator, would
place the patient at an unreasonably increased risk through participation in this
study

19. Patients who, in the judgment of the investigator, will be unlikely to comply with
the requirements of this protocol.